Tuesday, 29 October 2013

Thermal Power in Turkey, Market Outlook to 2025, 2013 Update

Reportstack has announced a new market report on Thermal Power in Turkey, Market Outlook to 2025, 2013 Update- - Capacity, Generation, Power Plants, Regulations and Company Profiles” is the latest report,  the industry analysis specialists that offer comprehensive information and understanding of the thermal power market in Turkey. The report provides in depth analysis on global thermal power market with forecasts up to 2025. The report analyzes the power market scenario in Turkey (includes thermal conventional, nuclear, large hydro, pumped storage and renewables) and provides future outlook with forecasts up to 2025. The research details thermal power market outlook in the country and provides forecasts up to 2025. The report highlights installed capacity and power generation trends from 2001 to 2025 in Turkey thermal power market. A detailed coverage of thermal energy policy framework governing the market with specific policies pertaining to thermal is provided in the report. The research also provides details of active thermal power plants in the country, upcoming thermal installation details and company snapshots of some of the major market participants.

Scope

The report analyses global thermal power market, Turkey power market and Turkey thermal power market. The scope of the research includes -
- A brief introduction on global carbon emissions and global primary energy consumption.
- Historical period is during 2001-2012 (unless specified) and forecast period is for 2013-2025.
- Detailed overview on the global thermal power market with installed capacity and generation trends, market forces analysis (drivers, restraints and challenges), installed capacity by fuel type, installed capacity split by region, installed capacity split by major countries and cross country comparison among thermal sources such as coal, oil and gas.
- Power market scenario in Turkey and provides detailed market overview, installed capacity and power generation trends by various fuel types (includes thermal conventional, nuclear, large hydro and renewables) with forecasts up to 2025.
- Detailed overview of Turkey thermal power market with installed capacity and generation trends, installed capacity by fuel type, net capacity addition by fuel type, owners share, market size of major equipments such as steam generator and turbine, and information on major active and upcoming projects.
- Key policies and regulatory framework supporting thermal power development.
- Company snapshots of some of the major market participants in the country.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to -
- Identify key growth and investment opportunities in Turkey thermal power market.
- Facilitate decision-making based on strong historic and forecast data for thermal power market.
- Position yourself to gain the maximum advantage of the industry’s growth potential.
- Develop strategies based on the latest regulatory events.
- Identify key partners and business development avenues.
- Understand and respond to your competitors’ business structure, strategy and prospects.

The Companies Mentioned in this report are Aksa Enerji Uretim A.S. Electricity Generation Company Enerjisa Enerji Uretim A.S. Iskenderun Enerji Uretim Ve Ticaret A.S.

To view the table of contents and know more details please visit  Thermal Power in Turkey, Market Outlook to 2025, 2013 Update  report. 

Similar Reports:

MediPoint: Drug-Eluting Balloons - US Analysis and Market Forecasts

Reportstack has announced a new market report on MediPoint: Drug-Eluting Balloons - US Analysis and Market Forecasts which is an essential source of information and analysis on the drug-eluting balloons (DEB) market in the US. The report provides in-depth insight into the use of DEB for coronary and peripheral applications in the lower extremity including in-stent restenosis, bifurcation lesions, small vessel disease, femoropopliteal artery and below-the-knee lesions, chronic total occlusions, acute myocardial infarction and lesions in diabetics.

The DEB market in the US was assessed to identify the unmet needs in the market, understand the regulatory challenges DEB manufacturers will encounter in the US, identify the challenges to adoption in clinical practice and evaluate future adoption of DEB for select coronary and peripheral indications. The US sales expectations are discussed through careful analysis of adoption patterns of using DEB. Clients can use this report to better understand the scope of this technology and for strategic planning to explore opportunities in this dynamic market. The report provides insights into the competitive landscape, the marketed and pipeline DEB products, the current and emerging players and comparative market analysis of different types of interventional techniques used to treat coronary and peripheral artery disease. This report is built using data and information sourced from secondary sources and primary research interviews and survey with leading Interventional Cardiologists and Interventional Radiologists, with in-house analysis conducted by team of industry experts.

Scope

- An overview of coronary artery disease and peripheral artery disease in the lower extremity, which includes epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines and modalities.
- Annualized total drug-eluting balloon market revenue by type of disease, annual cost of disease and drug-eluting balloons adoption pattern and procedure data in the US from 2010-2012 and forecast for seven years to 2019.
- Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement and regulatory considerations, evaluating market access and implications of the drug-eluting balloon market.
- Pipeline analysis: comprehensive data split across different stages of development, emerging trends and DEB designs in development, including investigation of DEB coating technology, antiproliferative agent used, balloon and catheter design and durability.
- Analysis of the current and future market competition in the US drug-eluting balloon market. Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends that will shape and drive the DEB market in the US.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the US DEB market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track device sales in the US DEB market by disease and indication from 2010-2019.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

The Companies Mentioned in this report are Aachen Resonance AnGes MG AngioScore AVIDAL Vascular B. Braun Biosensors International Biotronik Blue Medical Boston Scientific Corporation Caliber Therapeutics Cardionovum Concept Medical Research Cook Medical Covidien C.R. Bard DSM Biomedical Elixir Medical Corporation Eurocor LifeTech Scientific Corporation Medtronic Micell Technologies Minvasys TriReme Medical Vascular Nanotransfer Technologies.

To view the table of contents and know more details please visit MediPoint: Drug-Eluting Balloons - US Analysis and Market Forecasts report. 

Similar Reports:

The Commercial Helicopter Market 2013-2023

Reportstack has announced a new market report on The Commercial Helicopter Market 2013-2023 which is the result of extensive market and company research covering the global Commercial Helicopter industry. It provides detailed analysis of both historic and forecast global industry values, factors influencing demand, the challenges faced by industry participants, analysis of the leading companies in the industry, and key news. “The Global Commercial Helicopter Market 2013–2023” offers the reader detailed analysis of the global Commercial Helicopter market over the next ten years, alongside potential market opportunities to enter the industry, using detailed market size forecasts.

The global commercial helicopter sector is expected to experience a growth of 3.08% growth during the forecast period. The commercial helicopter market grows on the back of several sectors worldwide including offshore oil and gas exploration and production, HEMS, VIP transport, law enforcement and public safety etc. Europe and North America which are largest markets for civil helicopters are however saturated markets and thus are not expected to register considerable growth in their market size during the forecast period. Besides, the European market is also expected to experience a marginal decline owing to increased procurement in the first few years of the forecast period and a resultant lowered demand during the second half of the forecast period. Emerging markets of Asia Pacific, Latin America and Middle East are expected to provide the necessary boost to the industry during the forecast period.

“The Global Commercial Helicopter Market 2013–2023” provides detailed analysis of the current industry size and growth expectations from 2013 to 2023, including highlights of key growth stimulators. It also benchmarks the industry against key global markets and provides detailed understanding of emerging opportunities in specific areas.

Key Features and Benefits
The report provides detailed analysis of the market for Commercial Helicopter during 2013–2023, including the factors that influence why countries are investing or cutting helicopter expenditure. It provides detailed expectations of growth rates and projected total expenditure.

29% of the civil helicopters across the world are used for emergency medical services and law enforcement; however this segment is almost negligible in the context of China, India and Middle Eastern countries. Therefore, manufacturers like Bell Helicopter, Eurocopter, MD Helicopters and others are vying to attain a share in the EMS helicopters sector in these untapped markets. Eurocopter projects a requirement of approximately 50 helicopters for medical emergency services in India during the next few years. The government should formulate policies to waive off or charge minimal on jet fuel taxes, landing charges so as to make HEMS affordable during the forecast period.

Key Market Issues
With the fast-growing market for civil helicopters across the world, it is even difficult to fulfill the requirement of trained commercial pilots and technicians for service and support function. Market like China, which is expected to add additional 2000 and more helicopter during the forecast period, would at least require 6300 helicopter pilots. On one side, manufacturers like Bell helicopters is viewing China as a strong potential market in the Asia-Pacific region and are trying to increase the sales and simultaneously helping to overcome the challenge of lack of pilots by signing agreements with aviation colleges. Bell signed a memorandum of agreement with Guangzhou Civil Aviation College for helicopter-maintenance training facility in China which is anticipated to be operational by the end of 2013.Training by Bell is specific to the variants including Bell 206 and 407. Similarly the Indian market is witnessing the expanding scope of operation in civil aviation but is facing the challenge of lack of pilots and training facilities in the country.

Reforms are needed in the low-altitude airspace which is a major challenge in growing markets like China and India in order to boost the growing demand in the helicopter industry. Chinese civil aviation authority is streamlining the process and plans to expand the flying air space for civil helicopters by 2015. The reason the authorities are delaying the process is due to the threat that foreign air-carriers would monopolize the market with their established products. Additionally in India the lack of helipads and landing infrastructure will hinder the growth of helicopters. The infrastructure is non-existent in both urban and the remote areas creating worst times for the country during a disaster or emergency situation. The Rotary Wing Society of India (RWSI) is putting efforts in developing an authenticated registered directory of the operating and available helipads, which is currently lacking in the country. Limited airport airspace is another obstacle, where helicopter operations are majorly flying in Delhi and Mumbai, due to latter proximity to the sea-based oil rigs, airports are over-crowded with heavy air traffic due to fixed-wing operations which is resulting in lower slots and priority to the helicopter operators.

Key Highlights
North America and Europe have been the most important and prominent markets for commercial helicopter manufacturers until the last few years. However, the scenario has changed significantly in the recent years due to the saturation of the aforementioned markets due to which the growth was almost stagnant. Asia Pacific and Middle East are expected to be the growth centers for commercial helicopters during the forecast period owing to the huge potential in countries such as China, India, Australia, Japan, UAE, Qatar, etc. Additionally, the steadily growing oil and gas industry of the Middle Eastern countries is creating substantial demand for commercial helicopters to meet its increasing need for offshore transport in the coming years. EMS is also expected to be a considerable factor driving the market for civil helicopters in the Asia Pacific and Middle East during the forecast period, as countries in these regions still do not have an established EMS network compared to country in North America and Europe. Latin America is another region that is expected to witness robust demand for commercial helicopters registering a CAGR of 14.99% during the forecast period. This rapid growth in the region can be attributed to the strong economic growth in the countries such as Brazil and Mexico.

Even though light helicopters account for the smallest spending in the global commercial helicopter market during the forecast period, the segment is expected to grow robustly. This can be attributed to the rapidly increasing business from VIP or corporate transport and EMS firms and also the parapublic departments. In the present economic scenario, light helicopters are increasingly seen as a favorable choice by various organizations owing to their low price and latest technological advancements in the avionics and navigation systems. The global fleet of light helicopters as a percentage of larger helicopters fleet is thus increasing at a fast rate.

The Companies Mentioned in this report are AgustaWestland, Bell Helicopter, Eurocopter, Russian Helicopters, MD Helicopters, Robinson Helicopter Company, Aviation Industry Corporation of China
To view the table of contents and know more details please visit The Commercial Helicopter Market 2013-2023 report.

MediPoint: Trauma Fixation - US Analysis and Market Forecasts

Reportstack has announced a new market report on MediPoint: Trauma Fixation - US Analysis and Market Forecasts. Traumatic injury patients that come into the Emergency Room (ER) experience orthopedic injury in the form of fractures 60% to 65% of the time, based on conversations with key opinion leaders. Of this population, 45%–50% are operable and require fracture repair techniques in the form of external or internal fixation. As the global population continues to grow in the emerging markets, with overcrowding and economic growth, some of the drivers for trauma fixation include motor vehicle accidents and aging. The analysis shows that while the orthopedics implant market is mature, where products have become commodities, trauma fixation is one that has room for more technological development and adoption.

There are multiple drivers that contribute to the current state of the trauma fixation market. While factors such as reimbursement are currently not a challenge in the US for procedures and implants based on the proper indications, lowering physician reimbursement has driven orthopedic surgeons to seek other revenue streams and hold back some of the procedural numbers in joint replacement, stunting growth. This has in turn created more positive growth in plating and nail technology.

Scope

- An overview of bone trauma, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized US trauma fixation market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
- Investigation of current and future market competition for trauma fixation
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the trauma fixation sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as Orthopedic Surgeons.

Reasons to buy

- Understand the trends shaping and driving the US trauma fixation Market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in the US trauma fixation market through 2018.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What’s the next big thing in US trauma fixation market landscape? Identify, understand and capitalize.
The Companies Mentioned in this report are Acumed Biomet DePuy Synthes International Integra LifeSciences Orthofix OsteoMed Small Bone Innovations, Inc. Smith & Nephew Stryker Tornier Trimed Inc. Wright Medical Zimmer.

To view the table of contents and know more details please visit MediPoint: Trauma Fixation - US Analysis and Market Forecasts report.

Similar Reports:

PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022

Reportstack has announced a new market report on PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

These vaccines, which include a MenC conjugate vaccine and a heptavalent pediatric vaccine (DTP-Hib-HepB-IPV-MenC) are being developed and produced by government-sponsored institutions such as Bio-Manguinhos, Instituto Butantan, Fiocruz, and FUNED. Once they become widely available, these vaccines will quickly steal market share from private manufacturers because of their cost-effectiveness advantage.

Scope

- Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Brazil including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Brazil from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Brazil Meningococcal Vaccines market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Brazil
To view the table of contents and know more details please visit PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022 report. 
Similar Reports:

Menitorix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Reportstack has announced a new market report on Menitorix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

Menitorix (Meningococcal Groups C and Haemophilus b Tetanus Toxoid Conjugate Vaccine) is the brand name for GSK’s Hib-MenC conjugate vaccine sold in the UK and Spain. Approved in 2012, Menitorix was the first meningococcal conjugate vaccine to also provide protection against Hib.

Scope

- Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Menitorix including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Menitorix for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Menitorix performance
- Obtain sales forecast for Menitorix from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China).
To view the table of contents and know more details please visit Menitorix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 report. 
Similar Reports:

MnB rLP2086 (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Reportstack has announced a new market report on MnB rLP2086 (Meningococcal Vaccines) - Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

MnB rLP2086 is Pfizer’s recombinant protein vaccine that protects against MenB disease. Despite Pfizer’s position as a major player in the vaccine industry, MnB rLP2086 is currently the only meningococcal vaccine in the pharmaceutical giant’s portfolio. Originally developed by Wyeth, Pfizer acquired MnB rLP2086 with its purchase of the company in 2009. MnB rLP2086 is a bivalent vaccine composed of two variants of the N. meningitidis OMP LP2086, A05, and B01. LP086 is a lipoprotein (LP) linked to the outer membrane of the bacteria and promotes in vivo survival by binding Factor H and facilitating complement evasion.

Scope

- Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on MnB rLP2086 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for MnB rLP2086 for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of MnB rLP2086 performance
- Obtain sales forecast for MnB rLP2086 from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

To view the table of contents and know more details please visit MnB rLP2086 (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 report. 

Similar Reports: